

**ASX ANNOUNCEMENT**  
**18 MAY 2017**



## **COGSTATE SELECTED AS PREFERRED PROVIDER TO LILLY'S ALZHEIMER'S DISEASE PLATFORM**

Company to deliver novel solutions to ensure high-quality neuropsychological measures in clinical trials

Cogstate Ltd (ASX.CGS) is pleased to announce that it has been chosen as a preferred provider to the global healthcare leader, Eli Lilly and Company, to support their Alzheimer's disease platform with solutions to ensure high-quality neuropsychological outcome measures in clinical trials. Cogstate and Lilly will deploy an innovative program to improve the way that research sites train and collect endpoint data across Lilly's portfolio of Alzheimer's disease studies.

Underpinned by leading technology, Cogstate has brought together scientific experts with learning experts to create a novel, integrated program that drives efficiencies in rater training and certification, electronic clinical outcome assessment (eCOA) data capture, and risk-based central monitoring.

"We are excited to partner with Lilly to realize their vision for a portfolio-wide approach to endpoint quality assurance that reduces cycle times and lessens the burden on research sites," commented George Hunnewell, Chief Operating Officer for Cogstate. "By more efficiently and effectively preparing sites to administer neuropsychological assessments across all of Lilly's Alzheimer's studies, we dramatically improve the research experience for clinicians and patients while also ensuring greater reliability of the outcome measures."

Cogstate has supported more than 90 Alzheimer's disease studies across academic and clinical research with expertise and solutions that help guide decision-making for cognitive safety and efficacy.

### **Further Information for Investors**

The core of Cogstate's clinical trials business is the simplification and improvement of cognition measurement in drug development programs. This includes the large-scale deployment of our industry-leading computerized tests, as well as quality assurance support services for other traditional cognitive, functional and behavioral assessments in clinical trials. This support for other assessments has steadily increased over the last eight years, expanding our market share and increasing our total contract value per new business award.

This announcement concerns the provision of Cogstate services to support *traditional* measures of cognition, rather than Cogstate's computerised assessments. These traditional assessments are inherently prone to variability, bias and human error – so effective rater training and monitoring are key to a successful and conclusive study. Cogstate delivers training programs that

bridge the gap between the types of specialized assessments chosen for the clinical trial and the variability of skills and experience of individual raters at each clinical trial site. This includes rater qualification, training and certification followed by quality monitoring and periodic remediation, as needed.

Cogstate's designation as a Lilly preferred provider does not alone constitute an award of new business; rather it enables Cogstate to be awarded new contracts from Lilly in the future. Any future awards of new business will be announced in line with normal reporting of new business.

Lilly's Alzheimer's disease development pipeline is among the largest in the pharmaceutical industry and is available for review on their website at <https://www.lilly.com/pipeline/10.html>.

### **About Cogstate**

Cogstate Ltd (ASX:CGS) is a leading cognitive science company dedicated to simplifying the measurement of cognition in clinical trials, academic research and healthcare. Cogstate is a pioneer in commercialising rapid, reliable and highly sensitive computerised cognitive tests and provides expert support for neuropsychological and functional assessments to drive higher quality outcome measures in clinical trials. Cogstate customers include the world's leading biopharmaceutical companies; military and elite sporting organizations; physicians and patients; renowned academic institutions and public-private partnerships. For more information visit [www.cogstate.com](http://www.cogstate.com).

### **Investor contact:**

Brad O'Connor  
Cogstate Chief Executive Officer  
+613 9664 1300 or 0411 888 347  
[boconnor@cogstate.com](mailto:boconnor@cogstate.com)